Researchers tested VER-01, an experimental cannabis extract, on people with persistent lower back pain. Patients reported substantial relief after starting treatment, noting steady improvement over several months. Unlike smoking cannabis, this extract uses precise dosing and avoids harmful combustion products.
Lower back pain affects over 619 million people worldwide, making it the leading cause of disability. Many current therapies fall short. Opioids carry high addiction risks, while NSAIDs can damage the heart and digestive system with prolonged use. VER-01 could offer a safer alternative, giving patients meaningful improvement without these severe drawbacks.
Clinical Trial Reveals Significant Results
The late-stage trial enrolled 820 adults struggling with chronic lower back pain unrelieved by non-opioid drugs. Half of the participants received VER-01, produced by German company Vertanical, while the others received a placebo.
Researchers asked participants to record daily pain levels on a scale from 0 to 10. After three months, the VER-01 group reported an average 1.9-point reduction in pain, compared with 0.6 points in the placebo group.
Patients who continued treatment for six months experienced an additional 1.1-point decrease in pain. Alongside pain relief, they reported better sleep quality and improved mobility, both essential for maintaining daily function.
The study, published in Nature Medicine, confirmed that side effects remained manageable. Dizziness, nausea, and excessive tiredness occurred in some patients but faded with time. Importantly, researchers found no evidence of drug dependence or abuse.
Extract Differs Greatly from Smoking Cannabis
VER-01 comes from the Cannabis sativa plant but contains carefully controlled amounts of active compounds. Each dose provides 2.5 milligrams of THC, the psychoactive component of marijuana, combined with other naturally occurring cannabinoids.
Experts cautioned that the extract differs entirely from recreational cannabis use. Neuroscientist Jan Vollert explained that people should not assume smoking marijuana will achieve similar results. “Smoking cannabis and taking VER-01 are probably as similar as eating hazelnuts and eating Nutella,” he said, stressing their fundamental differences.
The study’s authors plan additional research comparing VER-01 directly with opioid therapies. If future trials confirm these findings, the extract could reshape pain management worldwide by providing effective relief without the dangers of current drugs. For millions facing relentless back pain, VER-01 may represent a long-awaited breakthrough.
